IGF2BP3 and cancer: More recently, cancer vaccination using the IGF2BP3 508-516 peptide along with the LY6K 177-186 and CDCA1 56-64 peptides was tested in a phase II open-label, non-randomized clinical trial in head and neck squamous cell cancer patients, indicating that a vaccination-induced immune response was positively correlated with a better prognosis (Yoshitake et al., 2015).